May 23, 2016

Medovex Corporation Attends Spine Week in Singapore

A Bi-Annual Congress Attended by 18 World Leading Spine Societies

ATLANTA, GA -- (Marketwired) -- 05/23/16 -- Medovex Corp. (NASDAQ: MDVX), a developer of medical technology products, today announced that as part of the Company's continuing worldwide expansion into the Asian Pacific Market and launch planning for the DenerveX™ System, the company attended Spine Week 2016. Spine Week is a bi-annual congress attended by 18 world leading spine societies was held from May 16 - 21, 2016 at the Marina Bay Sands Convention Centre in Singapore.

Spine Week is a highly recognized scientific congress and is attended by leading spine surgeons from Asia Pacific and around the world. Participants share the latest information, innovative techniques and procedures, best practices, and new technologies in spine surgery.

Spine week in Singapore represents the ideal platform to introduce our DenerveX System to spine surgeons and future distribution channels for the anticipated 2017 product launch throughout several Asian Pacific countries.

The Company's patented DenerveX System, currently in development and not yet commercially available, is designed to provide relief of pain associated with the facet joint. Lower back pain is the second most common cause of disability in the U.S. for adults. Studies indicate that 10% of the U.S. adult population suffers from lower back pain and that 31% of lower back pain is attributed to facet joint pain.

The DenerveX System consists of the DenerveX device, a single use device, and the DenerveX Pro-40 Power Generator. The DenerveX system is designed to provide a minimally invasive treatment option which combines two actions into one device. The combined technology is designed to provide a longer lasting solution and potential savings to the health care system.

Mr. Manfred Sablowski, Medovex Senior Vice President Sales & Marketing, stated, "We are excited to have participated at Spine Week 2016, an event involving 18 of the largest spine societies globally. It is clearly the place to introduce new technologies, much like our DenerveX System technology."

Sablowski continued, "Spine Week 2016 is a key meeting to connect with leading spine practitioners, as well as an opportunity to collaborate, develop relationships and interact, as we continue to prepare for our product launch Asia Pacific in 2017. The event provided us the opportunity to continue to identify leading key opinion leaders and distribution partners, as well as continue to develop strategies that we believe will help make our future launch a

success."

DenerveX is not yet CE marked or FDA cleared and is not yet commercially available.

About Medovex

Medovex was formed to acquire and develop a diversified portfolio of potentially ground breaking medical technology products. Criteria for selection include those products with potential for significant improvement in the quality of patient care combined with cost effectiveness. The Company's first pipeline product, the DenerveX device, is intended to provide long lasting relief from pain associated with facet joint syndrome at significantly less cost than currently available options. To learn more about Medovex Corp., visit www.medovex.com

Safe Harbor Statement

Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including without limitation those set forth in the Company's filings with the Securities and Exchange Commission (the "SEC"), not limited to Risk Factors relating to its patent business contained therein. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events or otherwise, except as required by law.

CONTACT INFORMATION

Medovex Corp.
Jason Assad
470-505-9905
Email Contact

Source: Medovex Corporation